Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Dec 3

PMID 25461627

Citations 17

Authors

Hiromi I Wettersten

Yosef Landesman

Sharon Friedlander

Sharon Shacham

Michael Kauffman

Robert H Weiss

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-1 (XPO1) inhibitor.

Materials And Methods: RCC cells were treated with the orally available XPO1 inhibitor, KPT-330, and cell viability and Annexin V (apoptosis) assays, and cell cycle analyses were performed to evaluate the efficacy of KPT-330 in two RCC cell lines. Immunoblotting and immunofluorescence analysis were performed to validate mechanisms of XPO1 inhibition. The efficacy and on-target effects of KPT-330 were further analyzed in vivo in RCC xenograft mice, and KPT-330-resistant cells were established to evaluate potential mechanisms of KPT-330 resistance.

Results: KPT-330 attenuated RCC viability through growth inhibition and apoptosis induction both in vitro and in vivo, a process in which increased nuclear localization of p21 by XPO1 inhibition played a major role. In addition, KPT-330 resistant cells remained sensitive to the currently approved for RCC multi-kinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (everolimus, temsirolimus), suggesting that these targeted therapeutics would remain useful as second line therapeutics following KPT-330 treatment.

Conclusion: The orally-available XPO1 inhibitor, KPT-330, represents a novel target for RCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-naïve as well as -resistant RCC patients.

Citing Articles

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.

Alhalabi O, Gouda M, Milton D, Momin H, Yilmaz B, Stephen B Cancer Med. 2025; 14(4):e70280.

PMID: 39945382 PMC: 11822648. DOI: 10.1002/cam4.70280.

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells.

Xu J, Wu S, Li G Exp Ther Med. 2023; 26(1):326.

PMID: 37346402 PMC: 10280315. DOI: 10.3892/etm.2023.12025.

Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα-NF-κB p65 Complex.

Chen J, Song D, Xu Y, Wu L, Tang L, Su Y Front Pharmacol. 2022; 13:896108.

PMID: 36110547 PMC: 9468713. DOI: 10.3389/fphar.2022.896108.

The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.

Landes J, Moore S, Bartley B, Doan H, Rady P, Tyring S J Cancer Res Clin Oncol. 2022; 149(5):2139-2155.

PMID: 35941226 DOI: 10.1007/s00432-022-04247-z.

Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors.

Marretta A, Di Lorenzo G, Ribera D, Cannella L, von Arx C, Bracigliano A Pharmaceutics. 2021; 13(9).

PMID: 34575598 PMC: 8466603. DOI: 10.3390/pharmaceutics13091522.

References

Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K . Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ. 2000; 7(8):721-8. DOI: 10.1038/sj.cdd.4400706. View

Senapedis W, Baloglu E, Landesman Y . Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014; 27:74-86. DOI: 10.1016/j.semcancer.2014.04.005. View

Dong Y, Chi S, Borowsky A, Fan Y, Weiss R . Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal. 2003; 16(2):263-9. DOI: 10.1016/s0898-6568(03)00136-0. View

Naniwa J, Kigawa J, Akeshima R, Kanamori Y, Itamochi H, Oishi T . Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cancer Sci. 2003; 94(12):1099-103. PMC: 11160253. DOI: 10.1111/j.1349-7006.2003.tb01406.x. View

Waldman T, Lengauer C, Kinzler K, Vogelstein B . Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996; 381(6584):713-6. DOI: 10.1038/381713a0. View

Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K . Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999; 18(5):1223-34. PMC: 1171213. DOI: 10.1093/emboj/18.5.1223. View

Weiss R, Lin P . Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006; 69(2):224-32. DOI: 10.1038/sj.ki.5000065. View

Weiss R, Borowsky A, Seligson D, Lin P, Dillard-Telm L, Belldegrun A . p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2006; 177(1):63-8. DOI: 10.1016/j.juro.2006.08.073. View

Nelson E, Evans C, Lara Jr P . Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007; 33(3):299-313. DOI: 10.1016/j.ctrv.2006.12.005. View

10.

Nickerson M, Jaeger E, Shi Y, Durocher J, Mahurkar S, Zaridze D . Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15):4726-34. PMC: 2629664. DOI: 10.1158/1078-0432.CCR-07-4921. View

11.

Turner J, Sullivan D . CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008; 15(26):2648-55. DOI: 10.2174/092986708786242859. View

12.

Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C . Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009; 65(1):153-9. DOI: 10.1227/01.NEU.0000348550.47441.4B. View

13.

Huang W, Yue L, Qiu W, Wang L, Zhou X, Sun Y . Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009; 32(6):E315. View

14.

Jung Y, Qian Y, Chen X . Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010; 22(7):1003-12. PMC: 2860671. DOI: 10.1016/j.cellsig.2010.01.013. View

15.

Cowey C, Hutson T . Molecularly targeted agents for renal cell carcinoma: the next generation. Clin Adv Hematol Oncol. 2010; 8(5):357-60, 361-4. View

16.

Koster R, di Pietro A, Timmer-Bosscha H, Gibcus J, van den Berg A, Suurmeijer A . Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010; 120(10):3594-605. PMC: 2947220. DOI: 10.1172/JCI41939. View

17.

Ljungberg B, Campbell S, Choi H, Cho H, Jacqmin D, Lee J . The epidemiology of renal cell carcinoma. Eur Urol. 2011; 60(4):615-21. DOI: 10.1016/j.eururo.2011.06.049. View

18.

Inoue H, Hwang S, Wecksler A, Hammock B, Weiss R . Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther. 2011; 12(9):827-36. PMC: 3225758. DOI: 10.4161/cbt.12.9.17680. View

19.

Makhov P, Golovine K, Kutikov A, Teper E, Canter D, Simhan J . Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther. 2012; 11(7):1510-7. PMC: 3491642. DOI: 10.1158/1535-7163.MCT-11-0907. View

20.

Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans C . CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2012; 189(6):2317-26. PMC: 4593314. DOI: 10.1016/j.juro.2012.10.018. View